With increasing information overload and packed work schedules, staying up-to-date on the newest oncologic advances is harder than ever. But take heart! The QuadShot is freshly brewed in your inbox four mornings each week so you can quickly down and digest the day's most pertinent cancer news.
The first large prospective study of 136 patients across 13 institutions receiving SMART for pancreatic cancer achieved local control in 83% and distant control in 51% of patients at one year with 3 patients experiencing grade 3+ toxicity. | Parikh, ASTRO 2022
Comments
Post a Comment